Mannkind Corporation
At a glance
Employees100-499
In business sinceNot reported
HeadquartersDanbury, CT
US patents268
SAM.gov UEIQJQAMVDWVBN8
CAGE code4ZCM1
Incorporated inDE
LEI213800GFBCNY1ZFST722
Brands
PipelineThis company sells these brands.
- fact sheet
- annual reports
- quarterly results
- SEC filings
- BluHale inhalation
- pediatric diabetes care
- furosemide injection
Named on the company’s own website, read JUL 29, 2026
What they make
CareersCareers page — seen SEP 8, 2026
Supplier designations
For Profit OrganizationManufacturer of Goods
Self-certified by the company in its SAM.gov registration
Patents
268 US patents granted 2003–2025, 52 of them in the five years to SEP 2025, including 30 design patents.
Pharmaceuticals 156Medical technology 28Organic fine chemistry 20Handling 14Measurement 11
- Diketopiperazine microparticles with defined specific surface areasUS 12,383,552 · granted AUG 12, 2025
- Method and composition for treating obesityUS 12,370,137 · granted JUL 29, 2025
- Prodrugs of treprostinilUS 12,357,599 · granted JUL 15, 2025
- Use of ultrarapid acting insulinUS 12,303,554 · granted MAY 20, 2025
- Multi-cartridge fluid delivery deviceUS 12,246,159 · granted MAR 11, 2025
Newest 5 shown · Granted to MannKind Corporation · PatentsView (USPTO), data through SEP 30, 2025 · CC BY 4.0
Their plant
| Facility | City | State | Employees | Status |
|---|---|---|---|---|
| Mannkind Corporation | Danbury | CT | 100–499 | ACTIVE |
Compiled from federal records — EPA, OSHA, SAM.gov and the U.S. Census — and from the company’s own website. Federal source data is public domain. Each plant’s page names the source of every field.


